A detailed history of Lindbrook Capital, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Lindbrook Capital, LLC holds 29,632 shares of VRTX stock, worth $13.4 Million. This represents 1.16% of its overall portfolio holdings.

Number of Shares
29,632
Previous 21,760 36.18%
Holding current value
$13.4 Million
Previous $10.2 Million 35.12%
% of portfolio
1.16%
Previous 0.97%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$460.0 - $505.78 $3.62 Million - $3.98 Million
7,872 Added 36.18%
29,632 $13.8 Million
Q2 2024

Jul 31, 2024

SELL
$392.81 - $485.53 $3.31 Million - $4.09 Million
-8,428 Reduced 27.92%
21,760 $10.2 Million
Q1 2024

Apr 25, 2024

BUY
$407.69 - $446.08 $7.74 Million - $8.47 Million
18,996 Added 169.73%
30,188 $12.6 Million
Q4 2023

Jan 31, 2024

BUY
$343.0 - $410.68 $1.77 Million - $2.12 Million
5,161 Added 85.57%
11,192 $4.55 Million
Q3 2023

Oct 25, 2023

SELL
$338.18 - $362.46 $1.81 Million - $1.94 Million
-5,345 Reduced 46.98%
6,031 $2.1 Million
Q2 2023

Jul 28, 2023

SELL
$314.42 - $351.91 $6.42 Million - $7.18 Million
-20,406 Reduced 64.21%
11,376 $4 Million
Q1 2023

Apr 26, 2023

SELL
$283.23 - $323.1 $44,467 - $50,726
-157 Reduced 0.49%
31,782 $10 Million
Q4 2022

Jan 24, 2023

BUY
$285.76 - $321.48 $6.91 Million - $7.78 Million
24,198 Added 312.6%
31,939 $0
Q3 2022

Nov 10, 2022

BUY
$273.83 - $305.53 $878,446 - $980,140
3,208 Added 70.77%
7,741 $2.24 Million
Q2 2022

Aug 01, 2022

BUY
$234.96 - $292.55 $413,999 - $515,473
1,762 Added 63.59%
4,533 $1.28 Million
Q1 2022

Apr 21, 2022

BUY
$221.42 - $260.97 $387,263 - $456,436
1,749 Added 171.14%
2,771 $723,000
Q4 2021

Jan 18, 2022

BUY
$177.01 - $223.45 $94,877 - $119,769
536 Added 110.29%
1,022 $224,000
Q3 2021

Nov 05, 2021

SELL
$181.39 - $202.99 $4,171 - $4,668
-23 Reduced 4.52%
486 $88,000
Q2 2021

Jul 27, 2021

SELL
$187.49 - $221.1 $2,624 - $3,095
-14 Reduced 2.68%
509 $103,000
Q1 2021

Apr 28, 2021

BUY
$207.02 - $241.31 $2,277 - $2,654
11 Added 2.15%
523 $112,000
Q4 2020

Jan 27, 2021

SELL
$207.01 - $276.09 $9,522 - $12,700
-46 Reduced 8.24%
512 $121,000
Q3 2020

Nov 03, 2020

BUY
$255.65 - $303.1 $16,361 - $19,398
64 Added 12.96%
558 $152,000
Q2 2020

Jul 27, 2020

SELL
$225.48 - $295.8 $1,803 - $2,366
-8 Reduced 1.59%
494 $143,000
Q1 2020

Apr 22, 2020

SELL
$199.77 - $247.81 $32,762 - $40,640
-164 Reduced 24.62%
502 $119,000
Q4 2019

Jan 27, 2020

SELL
$166.71 - $223.91 $10,836 - $14,554
-65 Reduced 8.89%
666 $146,000
Q3 2019

Oct 31, 2019

SELL
$166.23 - $187.09 $2,493 - $2,806
-15 Reduced 2.01%
731 $124,000
Q2 2019

Jul 24, 2019

BUY
$164.61 - $190.37 $2,798 - $3,236
17 Added 2.33%
746 $136,000
Q4 2018

Feb 07, 2019

BUY
$151.91 - $192.21 $110,742 - $140,121
729 New
729 $120,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.